Merkel cell carcinoma (MCC) patients experience fewer MCC-related recurrences and deaths after receiving pembrolizumab (Keytruda, Merck) post-surgery than those who received standard care alone, supporting a potential new adjuvant treatment option for this disease.
This is the main takeaway from EA6174 or STAMP, a Phase 3 trial presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
The study enrolled 293 patients who’d had surgery to remove their MCC and randomly assigned them to receive either pembrolizumab every three weeks for up to 17 doses or standard care after surgery. Most participants had Stage 3 MCC, and researchers assessed whether pembrolizumab could affect their chances of relapse, overall survival, and other disease-specific outcomes.
While the broadest relapse-free survival data showed some improvement, it did not meet statistical significance, but pembrolizumab significantly reduced the risk of distant spread of the cancer.
Investigators also examined the role of radiation therapy in treatment outcomes. Among patients who received radiation therapy, the benefit of pembrolizumab was maintained overall. The strongest effect was seen in patients who received radiation before starting pembrolizumab: The treatment improved relapse-free and distant-metastasis-free outcomes, the study showed. Pembrolizumab did not appear to improve outcomes when given concurrently with radiation.
Longer follow-up will be needed to determine the treatment’s effect on overall survival, conclude researchers who were led by Janice Mehnert, MD, Director of the Melanoma Medical Oncology Program and Associate Director of Clinical Research at Perlmutter Cancer Center at NYU Langone Health in New York, NY.
PHOTO CREDIT: DermNet